Why IMU is a multi multi bagger, page-25968

Correct, Imugene's preliminary reporting for last financial year.

I had an unbelievable visit today to my local doctors practice, and was consulted by a new doctor.
I was discussing cancer treatments in general and how far CD19 CAR T treatments for blood cancers have advanced in the last 5 years, and asked if he had heard of Imugene, he said yes and mentioned Azer-cel had a DLBCL patient booked in next week for an infusion on the CD19 CAR T trial at St Vincents Hospital.

What a coincidence, and who said that doctors where unaware of Imugene and Azer-cel in Australia.

"10 November 2023: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce dosing of the first patient in a Phase 1b clinical trial using azer-cel (allogeneic off-the-shelf CD19 CAR T, a type of cell therapy), manufactured and supplied from Imugene’s state-of-the-art facility in North
Carolina".
"The patient who was dosed at Banner Health (Phoenix Arizona) suffers from a difficult to
treat sub-set of NHL called Diffuse-Large B-cell lymphoma (DLBCL)"
.
"The Phase 1b allogeneic (allo) CAR T study is an ongoing multi-centre Phase 1b clinical trial
in patients with non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphocytic leukemia
(ALL). Azer-cel has demonstrated clinically meaningful activity with an acceptable safety
profile, including promising results in DLBCL patients who relapsed following CAR T".

I was unaware that an Azer-cel Phase 1b clinical trial was open to patients in Australia.

Regards.